Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor
作者： Tammie C. Yeh , Vivienne Marsh , Bryan A. Bernat , Josh Ballard , Heidi Colwell
DOI: 10.1158/1078-0432.CCR-06-1150
关键词:
摘要: … MEK1/2. The purpose of these studies has been to show the biological efficacy of ARRY-142886 (AZD6244) in enzymatic, … to inhibit MEK1/2 in their cellular environment was assayed by …
aacrjournals.org
highwire.org参考文章(32)
Judith S. Sebolt-Leopold, David T. Dudley, Roman Herrera, Keri Van Becelaere, Amy Wiland, Richard C. Gowan, Haile Tecle, Stephen D. Barrett, Alexander Bridges, Sally Przybranowski, W.R. Leopold, Alan R. Saltiel, Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Medicine. ,vol. 5, pp. 810- 816 ,(1999) , 10.1038/10533
Natalie G. Ahn, Theresa Stines Nahreini, Nicholas S. Tolwinski, Katheryn A. Resing, Pharmacologic inhibitors of MKK1 and MKK2. Methods in Enzymology. ,vol. 332, pp. 417- 431 ,(2001) , 10.1016/S0076-6879(01)32219-X
Peter Blume-Jensen, Tony Hunter, Oncogenic kinase signalling. Nature. ,vol. 411, pp. 355- 365 ,(2001) , 10.1038/35077225
J.D. Winkler, P.A. Lee, E. Wallace, G. Poch, K. Litwiler, T. Pheneger, J. Lyssikatos, M. Perrier, S.G. Eckhardt, T.C. Yeh, 342 Anti-tumor activity, pharmacokinetic and pharmacodynamic effects of the MEK inhibitor ARRY-142886 (AZD6244) in a BxPC3 pancreatic tumor xenograft model Ejc Supplements. ,vol. 2, pp. 103- 104 ,(2004) , 10.1016/S1359-6349(04)80349-5
Diana L. Brassard, Jessie M. English, Michael Malkowski, Paul Kirschmeier, T.L. Nagabhushan, W.Robert Bishop, Inhibitors of Farnesyl Protein Transferase and MEK1,2 Induce Apoptosis in Fibroblasts Transformed with Farnesylated but Not Geranylgeranylated H-Ras Experimental Cell Research. ,vol. 273, pp. 138- 146 ,(2002) , 10.1006/EXCR.2001.5440
Gretchen A. Repasky, Emily J. Chenette, Channing J. Der, Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends in Cell Biology. ,vol. 14, pp. 639- 647 ,(2004) , 10.1016/J.TCB.2004.09.014
Amy C Porter, Richard R Vaillancourt, Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis Oncogene. ,vol. 17, pp. 1343- 1352 ,(1998) , 10.1038/SJ.ONC.1202171
Bret B. Friday, Alex A. Adjei, K-ras as a target for cancer therapy. Biochimica et Biophysica Acta. ,vol. 1756, pp. 127- 144 ,(2005) , 10.1016/J.BBCAN.2005.08.001
Victoria Emuss, Mathew Garnett, Clive Mason, Richard Marais, , Mutations of C-RAF Are Rare in Human Cancer because C-RAF Has a Low Basal Kinase Activity Compared with B-RAF Cancer Research. ,vol. 65, pp. 9719- 9726 ,(2005) , 10.1158/0008-5472.CAN-05-1683
Muralidhar Beeram, Amita Patnaik, Eric K. Rowinsky, Raf: A Strategic Target for Therapeutic Development Against Cancer Journal of Clinical Oncology. ,vol. 23, pp. 6771- 6790 ,(2005) , 10.1200/JCO.2005.08.036